CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 22 enrolled
Drug / intervention
Lu AF35700drug
Likely dose
Lu AF35700 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02333487
NCT02333487Phase 1Completed
CompareCT.gov

Interventional, Open-label, Positron Emission Tomography (PET) Study Investigating D1 Dopamine, D2 Dopamine, and 5-HT6 Serotonin Receptor Occupancy After Multiple Oral Dosing of Lu AF35700 in Male Patients With Schizophrenia

H. Lundbeck A/S·interventional·Posted Jan 7, 2015·Updated May 12, 2020

In Brief

A Phase 1 clinical trial evaluating Lu AF35700 for Schizophrenia. Completed, enrolled 22 participants across 1 site.

Detailed Summary

The purpose of this PET study is to verify the binding of Lu AF35700 after multiple oral dosing at the dopamine and the serotonin receptors in male patients with schizophrenia.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJan 7, 2015
Enrollment StartDec 30, 2014
Primary CompletionFeb 11, 2016
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 11.5 years ago

Interventions

Lu AF35700drug

5 mg tablets for oral administration